ALK-Abello AS
$11
7
+$0.05+0.46% Monday 15:30
Statistics
Day High
11
Day Low
11
52W High
14.9
52W Low
8.2
Volume
100
Avg. Volume
11
Mkt Cap
2.84B
P/E Ratio
0
Dividend Yield
-
Dividend
-
Dividends
0%Dividend Yield
Mar 17
$0.98
Mar 16
$0.98
Mar 15
$0.98
Mar 14
$0.93
Mar 13
$0.87
Earnings
9NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.09
0.19
0.46
0.74
Expected EPS
N/A
Actual EPS
0.23
People Also Follow
This list is based on the watchlists of people on Stock Events who follow AKBLF. It's not an investment recommendation.
About
Biotechnology
Health Technology
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Show more...
CEO
Mr. Carsten Hellmann
Employees
2587
Country
DK
ISIN
DK0061802139
WKN
000A3DHX9